Antares Pharma Announces Positive Study Results with VIBEX MTX in Rheumatoid Arthritis Patients

Antares Pharma, Inc. AIS today announced the positive results of a clinical study evaluating VIBEX MTX, a proprietary auto injector product designed to give a rapid subcutaneous injection of methotrexate for the treatment of rheumatoid arthritis. The clinical pharmacokinetic study evaluated several dose strengths of MTX delivered by a healthcare professional to RA patients with VIBEX™MTX versus subcutaneous or intramuscular injection using a conventional needle and syringe. The primary end points were met with all three methods of administration providing equivalent performance in the patients studied, together with comparable safety.